Synonyms: ONO-1101 | ONO1101
landiolol is an approved drug (Japan and some European countries.)
Compound class:
Synthetic organic
Comment: Landiolol is an ultra short-acting, β1-adrenoceptor antagonist [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Landiolol is approved for clinical use in Japan and some European countries. It is administered intravenously to treat supraventricular tachycardia. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04931225 | LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS) | Phase 3 Interventional | Assistance Publique - Hôpitaux de Paris | ||
NCT05554978 | Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest | Phase 1/Phase 2 Interventional | Medical University of Vienna | ||
NCT05084118 | Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery | Phase 3 Interventional | Medical University of Vienna |